Proactively evaluate Amneal Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
|Event Date||Event Type||Company Name||Ticker Symbol||Drug Name||Therapy Area||Indication||Source Type|
|31 Dec 2021||GDCTXXXX||Lorem||Lorem||Lorem||XXXX||Planned||Lorem|
|21 Sep 2021||Phase I Trial Completion||Amneal Pharmaceuticals Inc||AMRX||vigabatrin||Central Nervous System||Complex Partial Seizure; Epilepsy; Seizures||Clinical Trial Registry|
|30 Apr 2021||Phase III Trial Completion||Amneal Pharmaceuticals Inc||AMRX||(carbidopa + levodopa)||Central Nervous System||Parkinson's Disease||Clinical Trial Registry|
|30 Oct 2020||Phase III Trial Completion||Amneal Pharmaceuticals Inc; AstraZeneca Plc; KI Health Partners LLC||AMRX; AZN||zolmitriptan||Central Nervous System||Migraine||Clinical Trial Registry|
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer